Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 12/20 | 0.49 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.49 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL369367 | 0.84 | CYP19A1 (0.45) | SCN9ASCN5ACYP19A1SCN3A | |
| SCHEMBL16239911 | 0.82 | MRGPRX4 (0.44) | SCN9ASCN5A | |
| SCHEMBL364125 | 0.80 | FFAR1 (0.54) | SCN9ASCN3A | |
| SCHEMBL680375 | 0.78 | SCN9A (0.50) | SCN9ASCN5A | |
| SCHEMBL367120 | 0.77 | HDAC8 (0.55) | SCN9ASCN5AXDH | |
| SCHEMBL366522 | 0.77 | MRGPRX4 (0.56) | SCN9ASCN5AALDH1A1 | |
| SCHEMBL679146 | 0.76 | SCN9A (0.52) | SCN9ASCN5ASCN3A | |
| SCHEMBL1690162 | 0.75 | SCN9A (0.46) | SCN9ASCN5A | |
| SCHEMBL680345 | 0.75 | EZH2 (0.47) | SCN9ASCN5ASCN3AALDH1A1HPGD | |
| SCHEMBL15094147 | 0.74 | SCN9A (0.53) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096500-B2 | Acyl sulfonamide compounds | PFIZER LIMITED (GB) | 2015-08-04 | — | — | US | disclosed |
| EP-2593428-B1 | N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | PFIZER LTD (GB) | 2014-11-19 | — | — | EP | disclosed |
| EP-2593428-A2 | N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | Pfizer Limited (GB) | 2013-05-22 | — | — | EP | disclosed |
| US-20130109701-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| WO-2012007868-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109701-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | SCN9A 16/4885CD274 4587/4885SCN5A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.